Optimizing activation and culture conditions for the production of cord blood‐derived CAR ‐T and natural killer cells
British Journal of Haematology · 2025-11 · 207 (5) · 1863-1873
DOI: 10.1111/bjh.70139 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 30.09.2025. Verfasst von Naokazu Nakamura und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Molecular and Medical Genetics, Center for Gene & Cell Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Fetal Blood, Killer Cells, Natural, Lymphocyte Activation, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: JSPS KAKENHI, Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Cord blood (CB) is gaining attention as a source of chimeric antigen receptor (CAR) T/NK cells. Many studies have focused on the therapeutic effects, but the methods of activating and culturing T/NK cells without excessive exhaustion during the initial stages of the production of CB‐derived CAR‐T/NK cells are yet to be established. The activation and culture conditions developed for peripheral blood (PB) CAR‐T/NK cells have been used for CB‐CAR‐T/NK cells, but there are differences in the composition and maturity of PB and CB lymphocytes. Thus, this study aims to optimize activation and culture conditions for the production of CB‐CAR‐T/NK cells. We compared different doses of various cytokines and found that the balance between activation and exhaustion was best with stimulation with a CD3/CD28 agonist followed by 40 U/mL interleukin (IL)‐7+ 40 U/mL IL‐15 for PB‐T cells; 40 U/mL IL‐2+ 40 U/mL IL‐7+ 40 U/mL IL‐15 for CB‐T cells; 40 U/mL IL‐2+ 40 U/mL IL‐15 for PB‐NK cells; and 40 U/mL IL‐2+ 200 U/mL IL‐15 for CB‐NK cells. Using killing assays, we confirmed that these cytokine protocols improved the anti‐tumour effects. These results will be useful for the development of CB‐CAR‐T/NK‐cell therapies and suggest the potential of these modalities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Molecular and Medical Genetics, Center for Gene & Cell Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
- Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
- Department of Neurology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.
ORCID-Profile: Naokazu Nakamura
Förderung
- JSPS KAKENHI
- Japan Agency for Medical Research and Development
Zitieren
APA
Nakamura, N., Liao, J., Soda, Y., Takahashi, M., Kodera, H., Kobari, Y., Hirai, Y., Takaori-Kondo, A., & Okada, T. (2025). Optimizing activation and culture conditions for the production of cord blood‐derived CAR ‐T and natural killer cells. British Journal of Haematology, 207(5), 1863-1873. https://doi.org/10.1111/bjh.70139
Vancouver
Nakamura N, Liao J, Soda Y, Takahashi M, Kodera H, Kobari Y, et al. Optimizing activation and culture conditions for the production of cord blood‐derived CAR ‐T and natural killer cells. British Journal of Haematology. 2025;207(5):1863-1873. doi:10.1111/bjh.70139
BibTeX
@article{Nakamura2025,
author = {Nakamura, Naokazu and Liao, Jiyuan and Soda, Yasushi and Takahashi, Mizuho and Kodera, Hiroto and Kobari, Yukage and Hirai, Yukihiko and Takaori-Kondo, Akifumi and Okada, Takashi},
title = {Optimizing activation and culture conditions for the production of cord blood‐derived CAR ‐T and natural killer cells},
journal = {British Journal of Haematology},
year = {2025},
volume = {207},
number = {5},
pages = {1863--1873},
doi = {10.1111/bjh.70139}
}
EUVIMED